Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Aspects of beta-amyloid as a biomarker for Alzheimer's disease.

Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H.

Biomark Med. 2007 Jun;1(1):59-78. doi: 10.2217/17520363.1.1.59.

PMID:
20477461
2.

A novel pathway for amyloid precursor protein processing.

Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K.

Neurobiol Aging. 2011 Jun;32(6):1090-8. doi: 10.1016/j.neurobiolaging.2009.06.002. Epub 2009 Jul 14.

PMID:
19604603
3.

Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization.

Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, Bowers MT.

J Am Chem Soc. 2009 May 13;131(18):6316-7. doi: 10.1021/ja8092604.

4.

Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.

Wasling P, Daborg J, Riebe I, Andersson M, Portelius E, Blennow K, Hanse E, Zetterberg H.

J Alzheimers Dis. 2009;16(1):1-14. doi: 10.3233/JAD-2009-0918. Review.

PMID:
19158416
5.

The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity.

Jan A, Gokce O, Luthi-Carter R, Lashuel HA.

J Biol Chem. 2008 Oct 17;283(42):28176-89. doi: 10.1074/jbc.M803159200. Epub 2008 Aug 11.

6.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
7.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
8.

Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.

Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K.

Expert Rev Proteomics. 2008 Apr;5(2):225-37. doi: 10.1586/14789450.5.2.225. Review.

PMID:
18466053
9.

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.

Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ.

J Neurosci. 2008 Apr 16;28(16):4231-7. doi: 10.1523/JNEUROSCI.5161-07.2008.

10.

Amyloid-related biomarkers for Alzheimer's disease.

Andreasen N, Zetterberg H.

Curr Med Chem. 2008;15(8):766-71. Review.

PMID:
18393845
11.

Variable phenotype of Alzheimer's disease with spastic paraparesis.

Karlstrom H, Brooks WS, Kwok JB, Broe GA, Kril JJ, McCann H, Halliday GM, Schofield PR.

J Neurochem. 2008 Feb;104(3):573-83. Epub 2007 Nov 6. Review.

12.

Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry.

Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A.

J Proteome Res. 2007 Nov;6(11):4433-9. Epub 2007 Oct 10.

PMID:
17927230
13.

PET imaging of amyloid deposition in patients with mild cognitive impairment.

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A.

Neurobiol Aging. 2008 Oct;29(10):1456-65. Epub 2007 May 11.

PMID:
17499392
14.

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.

Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL.

J Neurosci. 2007 Mar 14;27(11):2866-75.

15.

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.

Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K.

Neurosci Lett. 2006 Dec 6;409(3):215-9. Epub 2006 Oct 17.

PMID:
17049739
16.

The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families.

Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM.

Neurogenetics. 2006 Nov;7(4):277-9. Epub 2006 Aug 5.

17.

Alzheimer's disease.

Blennow K, de Leon MJ, Zetterberg H.

Lancet. 2006 Jul 29;368(9533):387-403. Review.

PMID:
16876668
18.

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C.

Hum Mutat. 2006 Jul;27(7):686-95.

PMID:
16752394
19.

Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families.

Yescas P, Huertas-Vazquez A, Villarreal-Molina MT, Rasmussen A, Tusié-Luna MT, López M, Canizales-Quinteros S, Alonso ME.

Neurogenetics. 2006 Jul;7(3):195-200. Epub 2006 Apr 21.

PMID:
16628450
20.

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.

Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K.

J Proteome Res. 2006 Apr;5(4):1010-6.

PMID:
16602710
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk